TNFRSF17 and Miyoshi myopathy: BCMA overexpression and constitutive activation are identified as a pathogenetic mechanism in MM in both preclinical and clinical studies, serving both as a diagnostic marker and a therapeutic target in novel treatment approaches [152,154,155].